Institution
Slovak Medical University
Education•Bratislava, Slovakia•
About: Slovak Medical University is a education organization based out in Bratislava, Slovakia. It is known for research contribution in the topics: Population & DNA damage. The organization has 751 authors who have published 1291 publications receiving 31553 citations. The organization is also known as: Sovak University of Health Sciences & Slovenská Zdravotnícka Univerzita v Bratislave.
Topics: Population, DNA damage, Comet assay, Pregnancy, Environmental exposure
Papers published on a yearly basis
Papers
More filters
University of Glasgow1, Brigham and Women's Hospital2, Yale University3, University of Copenhagen4, University of Missouri–Kansas City5, National University of Cordoba6, Wrocław Medical University7, Harvard University8, University of Minnesota9, Charles University in Prague10, Saarland University11, Taipei Veterans General Hospital12, National Yang-Ming University13, Slovak Medical University14, Fudan University15, University of Calgary16, Libin Cardiovascular Institute of Alberta17, Sofia Medical University18, University of Gothenburg19, Semmelweis University20, University of São Paulo21, Montreal Heart Institute22, University of Toronto23, Uppsala University24, University of Wisconsin-Madison25, AstraZeneca26
TL;DR: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes.
Abstract: Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-ind...
3,541 citations
Turku University Hospital1, National University of Ireland, Galway2, University of Catania3, University of Naples Federico II4, University of Paris5, Bispebjerg Hospital6, University of Sheffield7, University of Cambridge8, Stavanger University Hospital9, Oslo University Hospital10, Hospital Clínico San Carlos11, Mayo Clinic12, University of Western Brittany13, Rabin Medical Center14, Slovak Medical University15, Saarland University16, University of Barcelona17, University of Brescia18, University of Bern19, University of Erlangen-Nuremberg20, Leiden University Medical Center21
TL;DR: In this article, the authors present guidelines for the management of patients with coronary artery disease (CAD), which is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries.
Abstract: Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1.
3,448 citations
Papworth Hospital1, Katholieke Universiteit Leuven2, Charles University in Prague3, University of Amsterdam4, Aarhus University5, Wrocław Medical University6, Slovak Medical University7, University of Barcelona8, University of Toronto9, Hannover Medical School10, University College Dublin11, Complutense University of Madrid12, Medical University of Graz13, University of Paris-Sud14
TL;DR: Despite similarities in clinical presentation, operable and nonoperable CTEPH patients may have distinct associated medical conditions.
Abstract: Background—Chronic thromboembolic pulmonary hypertension (CTEPH) is often a sequel of venous thromboembolism with fatal natural history; however, many cases can be cured by pulmonary endarterectomy. The clinical characteristics and current management of patients enrolled in an international CTEPH registry was investigated. Methods and Results—The international registry included 679 newly diagnosed (≤6 months) consecutive patients with CTEPH, from February 2007 until January 2009. Diagnosis was confirmed by right heart catheterization, ventilation-perfusion lung scintigraphy, computerized tomography, and/or pulmonary angiography. At diagnosis, a median of 14.1 months had passed since first symptoms; 427 patients (62.9%) were considered operable, 247 (36.4%) nonoperable, and 5 (0.7%) had no operability data; 386 patients (56.8%, ranging from 12.0%– 60.9% across countries) underwent surgery. Operable patients did not differ from nonoperable patients relative to symptoms, New York Heart Association class, and...
742 citations
TL;DR: The reliability and reproducibility of the comet assay is reported, from the level of comparing results from duplicate gels prepared from the same sample of cells, up to an assessment of the natural intra‐ and interindividual variability in lymphocyte DNA damage measured in groups of normal, healthy human volunteers.
Abstract: The comet assay (single-cell gel electrophoresis), which measures DNA strand breaks at the level of single cells, is very easily applied to human lymphocytes, and therefore lends itself to human biomonitoring studies. For the examination of DNA base oxidation (a specific marker of oxidative damage), the assay is modified by including a stage at which the DNA is incubated with a suitable lesion-specific endonuclease. Here we report on the reliability and reproducibility of this approach, from the level of comparing results from duplicate gels prepared from the same sample of cells, up to an assessment of the natural intra- and interindividual variability in lymphocyte DNA damage measured in groups of normal, healthy human volunteers. We applied the assay in investigations of human disease and occupational exposure of factory workers.
635 citations
TL;DR: Among patients with locoregional clear-cell renal-cell carcinoma at high risk for tumor recurrence after nephrectomy, the median duration of disease-free survival was significantly longer in the sunitinib group than in the placebo group, at a cost of a higher rate of toxic events.
Abstract: BackgroundSunitinib, a vascular endothelial growth factor pathway inhibitor, is an effective treatment for metastatic renal-cell carcinoma. We sought to determine the efficacy and safety of sunitinib in patients with locoregional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy. MethodsIn this randomized, double-blind, phase 3 trial, we assigned 615 patients with locoregional, high-risk clear-cell renal-cell carcinoma to receive either sunitinib (50 mg per day) or placebo on a 4-weeks-on, 2-weeks-off schedule for 1 year or until disease recurrence, unacceptable toxicity, or consent withdrawal. The primary end point was disease-free survival, according to blinded independent central review. Secondary end points included investigator-assessed disease-free survival, overall survival, and safety. ResultsThe median duration of disease-free survival was 6.8 years (95% confidence interval [CI], 5.8 to not reached) in the sunitinib group and 5.6 years (95% CI, 3.8 to 6.6) in the placebo gr...
581 citations
Authors
Showing all 759 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Florian Lang | 116 | 1421 | 66496 |
| Jaromir Pastorek | 62 | 169 | 14221 |
| Peter Boor | 50 | 260 | 7836 |
| Péter Hegyi | 45 | 403 | 8105 |
| August Heidland | 45 | 400 | 7040 |
| Tomas Trnovec | 38 | 156 | 4675 |
| Anton Kočan | 35 | 90 | 3190 |
| Gaetano Isola | 35 | 129 | 2304 |
| Maria Dusinska | 34 | 51 | 6761 |
| Katarína Šebeková | 33 | 144 | 3246 |
| Tammo Ostendorf | 32 | 64 | 3061 |
| Vladimir Krcmery | 31 | 282 | 4584 |
| Kvetoslava Koppova | 30 | 61 | 6179 |
| Juraj Majtan | 29 | 84 | 2327 |
| Brigitte Laguerre | 25 | 113 | 3278 |